Opportunistic biotech trading bitch with a focus on nucleic acid-based and -targeted biotech. Fiercely independent. https://t.co/dfLqOuH7Uh
Cite asCryptoQuant has tracked the directional calls on IONS by @RNAiAnalyst on X since Aug 2025: not yet scored on IONS (as of Nov 11, 2026).
Other assets covered (14)
9 IONS calls on record, a thin history.
Relative view by default: fewer than 30 IONS calls or days on record.
Sentiment timeline shows relative sentiment within this analyst's history. A perma-bull showing 8 bullish : 2 bearish in a bear market sets that as their baseline. If you notice any errors, claim @RNAiAnalyst to submit corrections.
Hover the chart to read the thesis of that period · click a day to pin it
$ARWR $IONS both companies had told Street to lower its expectations and had been punished for it. But even I did never expect such a horrendous $9M print. Reversion to the mean trade here?
View original →$IONS shocker: just $9M in Q3 sales ofApoc3 trig-lowering ASO. Good/bad for $ARWR? https://t.co/g2yekCVqh1
View original →It took a dirty ASO to make real progress against #HBV. The clean RNAi alternatives are not as effective. The paragraphs below say it all. $IONS $ARWR $ABUS https://t.co/0y9IP2f9zg https://t.co/5WcniklpjS
View original →$IONS with their PS ASO side effects are really muddying the water regarding how we think about drug targets. Most recent example is tau and the supposed non dose-responsivness of therapeutic efficacy. $arwr
View original →
